Cigna earnings beat by $0.04, revenue topped estimates
Mckesson Corp ’s stock reached an all-time high of $733.10, reflecting a strong performance for the $91 billion healthcare giant. According to InvestingPro, the company maintains a "GREAT" financial health score, supported by robust revenue growth of 16.2% over the past year. This milestone underscores the company’s robust growth trajectory, with its stock price appreciating by 21.23% over the last twelve months. This remarkable increase highlights investor confidence and the company’s successful strategies in navigating the healthcare sector’s challenges. The stock’s ascent to this new peak marks a significant achievement for Mckesson, as it continues to capitalize on market opportunities and expand its influence in the industry. InvestingPro analysis shows the company has maintained dividend payments for 32 consecutive years, with recent dividend growth of 14.5%. For deeper insights and access to 14 additional ProTips about Mckesson, explore the comprehensive Pro Research Report available on InvestingPro.
In other recent news, McKesson Corporation (NYSE:MCK) has reported significant developments that are capturing the attention of investors. The company posted strong financial results for Q3 2025, with adjusted earnings per share (EPS) of $10.12, exceeding forecasts of $9.81. However, revenue fell short of expectations at $90.82 billion against a projected $93.48 billion. In a strategic move, McKesson completed the acquisition of a 70% stake in Core Ventures for approximately $2.49 billion, aiming to enhance community-based oncology care. Analyst firms have reacted positively to McKesson’s recent performance and strategic direction. Morgan Stanley (NYSE:MS) raised its price target for McKesson to $770, maintaining an Overweight rating, while Jefferies increased its target to $800 with a Buy rating, citing the company’s robust earnings and promising guidance for fiscal year 2026. Meanwhile, Wells Fargo (NYSE:WFC) maintained its Equal Weight rating with a price target of $766, acknowledging a slight increase in full-year EPS guidance. These developments highlight McKesson’s focus on strengthening its core business areas and expanding its oncology and specialty solutions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.